291 related articles for article (PubMed ID: 29917079)
1. The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis.
Svensson EM; Svensson RJ; Te Brake LHM; Boeree MJ; Heinrich N; Konsten S; Churchyard G; Dawson R; Diacon AH; Kibiki GS; Minja LT; Ntingiya NE; Sanne I; Gillespie SH; Hoelscher M; Phillips PPJ; Simonsson USH; Aarnoutse R
Clin Infect Dis; 2018 Jun; 67(1):34-41. PubMed ID: 29917079
[TBL] [Abstract][Full Text] [Related]
2. Greater Early Bactericidal Activity at Higher Rifampicin Doses Revealed by Modeling and Clinical Trial Simulations.
Svensson RJ; Svensson EM; Aarnoutse RE; Diacon AH; Dawson R; Gillespie SH; Moodley M; Boeree MJ; Simonsson USH
J Infect Dis; 2018 Aug; 218(6):991-999. PubMed ID: 29718390
[TBL] [Abstract][Full Text] [Related]
3. Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients.
Heinrich N; Dawson R; du Bois J; Narunsky K; Horwith G; Phipps AJ; Nacy CA; Aarnoutse RE; Boeree MJ; Gillespie SH; Venter A; Henne S; Rachow A; Phillips PP; Hoelscher M; Diacon AH; ;
J Antimicrob Chemother; 2015 May; 70(5):1558-66. PubMed ID: 25630641
[TBL] [Abstract][Full Text] [Related]
4. A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses.
Svensson RJ; Aarnoutse RE; Diacon AH; Dawson R; Gillespie SH; Boeree MJ; Simonsson USH
Clin Pharmacol Ther; 2018 Apr; 103(4):674-683. PubMed ID: 28653479
[TBL] [Abstract][Full Text] [Related]
5. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic/pharmacodynamic analysis of an intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis.
Te Brake L; Dian S; Ganiem AR; Ruesen C; Burger D; Donders R; Ruslami R; van Crevel R; Aarnoutse R
Int J Antimicrob Agents; 2015 May; 45(5):496-503. PubMed ID: 25703312
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis.
Ngo HX; Xu AY; Velásquez GE; Zhang N; Chang VK; Kurbatova EV; Whitworth WC; Sizemore E; Bryant K; Carr W; Weiner M; Dooley KE; Engle M; Dorman SE; Nahid P; Swindells S; Chaisson RE; Nsubuga P; Lourens M; Dawson R; Savic RM
Clin Infect Dis; 2024 Jun; 78(6):1680-1689. PubMed ID: 38462673
[TBL] [Abstract][Full Text] [Related]
8. Standard versus high dose of rifampicin in the treatment of pulmonary tuberculosis: a systematic review and meta-analysis.
Onorato L; Gentile V; Russo A; Di Caprio G; Alessio L; Chiodini P; Coppola N
Clin Microbiol Infect; 2021 Jun; 27(6):830-837. PubMed ID: 33813119
[TBL] [Abstract][Full Text] [Related]
9. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.
Nijland HM; Ruslami R; Suroto AJ; Burger DM; Alisjahbana B; van Crevel R; Aarnoutse RE
Clin Infect Dis; 2007 Oct; 45(8):1001-7. PubMed ID: 17879915
[TBL] [Abstract][Full Text] [Related]
10. Artificial intelligence-derived 3-Way Concentration-dependent Antagonism of Gatifloxacin, Pyrazinamide, and Rifampicin During Treatment of Pulmonary Tuberculosis.
Pasipanodya JG; Smythe W; Merle CS; Olliaro PL; Deshpande D; Magombedze G; McIlleron H; Gumbo T
Clin Infect Dis; 2018 Nov; 67(suppl_3):S284-S292. PubMed ID: 30496458
[TBL] [Abstract][Full Text] [Related]
11. The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis.
Sirgel FA; Fourie PB; Donald PR; Padayatchi N; Rustomjee R; Levin J; Roscigno G; Norman J; McIlleron H; Mitchison DA
Am J Respir Crit Care Med; 2005 Jul; 172(1):128-35. PubMed ID: 15805182
[TBL] [Abstract][Full Text] [Related]
12. [The therapeutic effect of regimens containing isoniazid and rifampicin for pulmonary tuberculosis with single isoniazid or rifampicin resistance].
Tan S; Ding X; Tan Y; Cai X; Li Y
Zhonghua Jie He He Hu Xi Za Zhi; 2014 Dec; 37(12):915-8. PubMed ID: 25609129
[TBL] [Abstract][Full Text] [Related]
13. Individualised dosing algorithm and personalised treatment of high-dose rifampicin for tuberculosis.
Svensson RJ; Niward K; Davies Forsman L; Bruchfeld J; Paues J; Eliasson E; Schön T; Simonsson USH
Br J Clin Pharmacol; 2019 Oct; 85(10):2341-2350. PubMed ID: 31269277
[TBL] [Abstract][Full Text] [Related]
14. High-dose rifampicin in tuberculosis: Experiences from a Dutch tuberculosis centre.
Seijger C; Hoefsloot W; Bergsma-de Guchteneire I; Te Brake L; van Ingen J; Kuipers S; van Crevel R; Aarnoutse R; Boeree M; Magis-Escurra C
PLoS One; 2019; 14(3):e0213718. PubMed ID: 30870476
[TBL] [Abstract][Full Text] [Related]
15. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial.
Ruslami R; Ganiem AR; Dian S; Apriani L; Achmad TH; van der Ven AJ; Borm G; Aarnoutse RE; van Crevel R
Lancet Infect Dis; 2013 Jan; 13(1):27-35. PubMed ID: 23103177
[TBL] [Abstract][Full Text] [Related]
16. Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials.
Savic RM; Weiner M; MacKenzie WR; Engle M; Whitworth WC; Johnson JL; Nsubuga P; Nahid P; Nguyen NV; Peloquin CA; Dooley KE; Dorman SE;
Clin Pharmacol Ther; 2017 Aug; 102(2):321-331. PubMed ID: 28124478
[TBL] [Abstract][Full Text] [Related]
17. Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia.
van Crevel R; Alisjahbana B; de Lange WC; Borst F; Danusantoso H; van der Meer JW; Burger D; Nelwan RH
Int J Tuberc Lung Dis; 2002 Jun; 6(6):497-502. PubMed ID: 12068982
[TBL] [Abstract][Full Text] [Related]
18. Concentrations of rifampicin in pre-dose samples in patients with pulmonary tuberculosis.
Uchoa BKB; Albério CAA; Pinto ACG; de Medeiros Araujo Lucena S; Vieira JLF
Braz J Infect Dis; 2019; 23(2):130-133. PubMed ID: 31128081
[TBL] [Abstract][Full Text] [Related]
19. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
Wada M
Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial.
Milstein M; Lecca L; Peloquin C; Mitchison D; Seung K; Pagano M; Coleman D; Osso E; Coit J; Vargas Vasquez DE; Sanchez Garavito E; Calderon R; Contreras C; Davies G; Mitnick CD
BMC Infect Dis; 2016 Aug; 16(1):453. PubMed ID: 27567500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
